Thiogenesis Therapeutics, Corp. (TTI.V)
| Previous Close | 0.7700 |
| Open | 0.7200 |
| Bid | 0.7200 x N/A |
| Ask | 0.7400 x N/A |
| Day's Range | 0.7000 - 0.7400 |
| 52 Week Range | 0.6000 - 1.0600 |
| Volume | |
| Avg. Volume | 11,069 |
| Market Cap | 33.667M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part I - Scientific and Medicinal Product Documentation, for its lead compound TTI-
- Newsfile
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release of December 18, 2023, it has closed a second and final tranche of its non-brokered private placement, originally announced on November 20, 2023 (the "Offering"). Under this second tranche, the Company has issued 417,000 common shares for gross proceeds of C$312,750. The Company paid cash ...
